<DOC>
	<DOCNO>NCT02238834</DOCNO>
	<brief_summary>This randomize , placebo control , single multiple ascend dose study assess safety tolerability pharmacokinetics FP-025 healthy subject .</brief_summary>
	<brief_title>Phase 1 Safety , Tolerability Pharmacokinetics ( PK ) Study FP-025 Healthy Volunteers</brief_title>
	<detailed_description>In SAD part study investigational drug administer dose escalation manner start 200 mg Cohort 1 2000 mg Cohort 6 . The study drug orally take capsule . In MAD part study investigational drug administrate twice daily 5 day depend half-life FP-025 , determine SAD part study . Study subject randomize 1:3 ratio either placebo FP-025 every cohort SAD MAD part study .</detailed_description>
	<criteria>Males age ≥18 ≤55 year BMI ≥18 kg/m2 ≤32 kg/m2 . A rest pulse ≥50 bpm ≤100 bpm Screening Visit . A rest systolic blood pressure ≤140 mmHg rest diastolic blood pressure ≤90 mmHg Screening Visit . Baseline laboratory test value within reference range base blood urine sample take Screening Visit . Out normal range value ( except liver parameter ) may accept investigator , clinically significant . The subject , opinion investigator , generally healthy base assessment medical history , physical examination , vital sign , electrocardiogram ( ECG ) , result haematology , clinical chemistry , urinalysis , serology , laboratory test . Adequate contraception ( doublebarrier ) apply 3 month completion study . Signed Informed Consent prior study related procedure . Ability communicate well investigator , local language , understand comply requirement study . The subject take disallowed medication within 1 week prior first dose study product ( within 5 halflives prior inclusion medication ingest , whichever long ) . The subject substance abuserelated disorder significant history drug alcohol abuse , define alcohol intake great 21 unit per week history drug abuse history substance abuse deem significant investigator . The subject avoid alcohol least 5 day admission clinic . The subject take investigational product within 30 day prior first dose study product . The subject history severe drug allergy hypersensitivity food allergy . The subject history presence clinically significant immunological , cardiovascular , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological ( particular diabetes prediabetes ) , haematological , dermatological , venereal , neurological , chronic infectious psychiatric disease major disorder . The subject history cancer , basal cell Stage 1 squamous cell carcinoma skin , remission least 5 year prior first dose study product . The subject history abdominal surgery ( exclude laparoscopic cholecystectomy uncomplicated appendectomy ) thoracic nonperipheral vascular surgery within 6 month prior first dose study product . The subject concurrent illness may affect particular target absorption , distribution , elimination study product . The subject clinically significant illness within 4 week prior first dose study product . The subject surgery trauma significant blood loss within last 3 month prior first dose study product . The subject donate blood within 3 month prior first dose study product . The subject test positive human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( antiHCV ) . The subject current smoker use nicotine containing product . Exsmokers must cease smoking least 6 month prior first dose study product ( + &lt; 10 pack year ) . The subject avoid glutamate rich food admission study . The subject test positive Screening Visit Safety Baseline Visit drug abuse ( opiate , methadone , cocaine , amphetamine ( include ecstasy ) , barbiturates , benzodiazepine cannabinoids ) . The subject 's correct QT interval ( QTc ) ( Bazett 's Fridericia 's correction ) &gt; 450 m read printout ECG produce ECG equipment evaluate investigator Screening Visit . An outofrange abnormal ECG may repeat . In total , 3 ECGs record consecutively investigator must evaluate triplicate ECG . If subject 's QTc &gt; 450 m least 2 ECGs , subject must exclude . The subject exercise extensively ( e.g . marathon , triathlon similar high energetic sport ) . In general , subject refrain sport least 4 day participation study . The subject , opinion investigator , unlikely comply clinical study protocol unsuitable reason . A history psychiatric disease , i.e depression and/or anxiety relate illness . Serum creatinine , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) upper limit normal ( ULN ) screening . Hemoglobin , white blood cell ( WBC ) platelet count lower limit normal ( LLN ) screening . Other laboratory result clinically significant abnormal screening . Legal incapacity limit legal capacity screening . Employees investigator study centre , well first grade family member employee investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Safety tolerability</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Randomized</keyword>
	<keyword>Double Blind</keyword>
	<keyword>Placebo-Controlled</keyword>
	<keyword>Single- &amp; Multiple Dose Escalation</keyword>
	<keyword>FP-025</keyword>
	<keyword>MMP-12 inhibitor</keyword>
</DOC>